Asimov Stock

asimov.comHealthcareFounded: 2017Funding to Date: $241.8MM

Asimov is a biotech company that specializes in research and development of gene therapies. In addition to the therapies it researches, Asimov provides a technology platform that scientists and geneticists can utilize to research prospective genetic treatments. The private company’s platform contains a genetic informational library and design software for simulation of synthetic biological processes.

Register for Details

For more details on financing and valuation for Asimov, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Asimov.

Register Today

Team

Management Team

Alec Nielsen
Founder and Chief Executive Officer
Christopher Voigt
Co-Founder
Raja Srinivas
Founder
Douglas Densmore
Founder
Kevin D. Smith
Head of Technology Development

Board Members

Vijay Pande
Andreessen Horowitz

Other companies like Asimov in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

What’s the holy grail of biology? This startup says it’s engineerable cells, and with $200million of new funding for their CAD platform to program genetic circuits, the manufacture of biological therapeutics is set to radically change. Read how: